A randomized controlled clinical study of karanjadi vati and rosuvastatin tablet in the management of medovridhhi with special reference to hyperlipidaemia.

ASHISH KECHE0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1)Patient having Serum LDL Cholesterol Level above 190mg/dl.
•2) According to NCEP ATP III, Patient having multiple (+2) risk factor with 10 year risk of 10% of CHD whose LDL Cholesterol goals not achieve (>=160mg/dl) after 12 weeks Therapeutic lifestyle changes (TLC).
•3)According to NCEP ATP III, Patient having multiple (+2) risk factor with 10 year risk of 10% to 20% of CHD whose LDL Cholesterol goals not achieve (>=130mg/dl) after 12 weeks Therapeutic lifestyle changes (TLC).

•1)Patient with Multiple (+2) risk factor with 10 year risk 10% of CHD, who achieve the goal of LDL Cholesterol (<=160mg/dl) after TLC therapy.
•2)Patient with Multiple (+2) risk factor with 10 year risk 10% to 20% of CHD, who achieve the goal of LDL Cholesterol (<=130mg/dl) after TLC therapy.
•3)Pregnant women and lactating mothers.
•4)Patients having history of Renal Disease, Liver Disease.
•5)Patients having Recently 3 month history of Heart Failure or Stroke.
•6)Patients having disorders like Carcinoma etc. anywhere in the body.

发起方

ASHISH KECHE